Yaron Werber

Citi Investment Research analyst Yaron Werber has kept the target price of $57 per share unchanged for Gilead Sciences Inc. (NASDAQ: GILD), stating that the consensus numbers look conservative and further upside is possible given Gilead’s substantial expense leverage and potential for a better top...

Yaron Werber of Citi maintained his "buy" rating on Amgen Inc (NASDAQ: AMGN). The target price for AMGN is set to $64.00. According to Citi, the market has overlooked competition to Amgen’s Epogen and Aranesp from Hematide. Citi expects this drug to pose threat to AMGN's base business from late...